GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » 3-Year EPS without NRI Growth Rate

Novo Nordisk A/S (Novo Nordisk A/S) 3-Year EPS without NRI Growth Rate : 26.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S 3-Year EPS without NRI Growth Rate?

Novo Nordisk A/S's EPS without NRI for the three months ended in Dec. 2023 was $0.72.

During the past 12 months, Novo Nordisk A/S's average EPS without NRI Growth Rate was 39.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 26.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Novo Nordisk A/S was 38.20% per year. The lowest was -2.90% per year. And the median was 18.60% per year.


Competitive Comparison of Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate falls into.



Novo Nordisk A/S 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Novo Nordisk A/S  (OTCPK:NONOF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Novo Nordisk A/S 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.